New Delhi: CDSCO warns of 4 drugs, including Shelcal 500 calcium supplement and Pan D, as being fake. Moreover, 49 other drugs samples where also confirmed to be substandard in quality thus posing a serious threat to consumers in the whole pharmaceutical market.
The drugs identified include branded particles from standard producers, for example, camila pharmaceutical, alkem health science, aristo pharmaceutical, innova captan, hindustan antibiotics and ipca laboratories. The September monthly drug alert report revealed that paracetamol, Pan D, calcium, and vitamin D-3 were classified as counterfeit, while other medications like oxytocin, metronidazole, and fluconazole were included in the “quality deficiency” list.
The Regulatory Response and Inspections element is concerned with the ways in which regulation and inspections are carried out and their effects on organisations.
R.C. Singh, Drug Controller General of India confirmed that to cheque the percentage of the substandard drugs in circulation there are frequent raids are conducted. He wanted to assert that due to remarkable monitoring and action undertaken by the CDSCO the quantity of substandard drugs has been considerably reduced in consumers end.
Of the nearly 3,000 samples of medicines, 49 samples were rejected and referred to as substandard, a little less than 2% of the samples that were tested. Raghuvanshi went on to explain that consumers should understand that if a particular lot was not produced to quality standards, it does not mean that all products branded the same name are inferior. “Only that particular batch is deemed non-compliant with quality standards,” an official source noted.
What? Such as long-standing concerns of the quality of medications?
The CDSCO’s findings came after a similar report in August that showed over 50 medications, including paracetamol, Pan D, calcium, vitamin D-3 and some anti-diabetic, have quality concerns. The exposure of fake and low-quality medicines in supply chain point to the perennial problems in the Indian Pharmaceutical Systems and why Callas’ oversight of the supply chain is crucial.